Correlation between p53 immunoexpression and TP53 mutation status in extrapulmonary small cell neuroendocrine carcinomas and its association with patient survival
Rattachement africain : cz. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Extrapulmonary small cell neuroendocrine carcinoma (EP-SCNC) is a rare malignancy with a poor prognosis. Despite its morphological similarity to lung small cell carcinomas, its oncogenesis remains uncertain. One hundred and seventy-one EP-SCNC were enrolled in a multicenter study, and all tissue samples underwent an immunohistochemical p53 analysis. One hundred twenty-five samples were molecularly analyzed using next-generation sequencing (NGS), comprising DNA and RNA analysis. p53 normal/wild type expression was detected in 68 cases (39.8%), whereas aberrant expression was detected in 103 cases (60.2%). Molecular TP53 alteration was detected in 92 out of 125 tumors (73.6%). The TP53 mutation was shown to be prognostic and associated with shorter overall survival (p = 0.041). The multivariate analysis of p53 and TP53 mutational status found that it impacted overall survival relative to distinct sites of tumor locations (p = 0.004 and p = 0.001, respectively). Age did not influenced survival in the multivariate analysis of p53 and TP53 (p = 0.002; p < 0.001 resp.). Among tumors with paired immunohistochemical and molecular results, 108 exhibited concordance between the immunohistochemical and molecular analysis, whereas 17 were discordant. Accordingly, p53 aberrant expression was tightly associated with a TP53 mutation (p < 0.001). In discordant cases, molecular analysis revealed no alteration in three tumors with p53 overexpression. In contrast, in 14 tumors with wild-type p53 expression, TP53 genetic alteration was detected. Possible causes of discordance are discussed in this manuscript. Furthermore, the incidence of aberrant p53 expression / TP53 molecular alteration was noticeably lower in EP-SCNC than in small-cell lung carcinomas. Therefore, in EP-SCNC, other driver mutations should be sought since personalized therapy can improve patient prognosis.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Correlation between p53 immunoexpression and TP53 mutation status in extrapulmonary small cell neuroendocrine carcinomas and its association with patient survival
- Date Crossref
- 23/01/2025
- Éditeur
- Springer Science and Business Media LLC
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Charles University Department of Pathology pays non établi dans la noticeUniversité ou école supérieure
-
Thomayer University Hospital Department of Pathology and Molecular Medicine pays non établi dans la noticeÉtablissement de santé
-
General University Hospital in Prague pays non établi dans la noticeOrganisme public
-
University Hospital Kralovske Vinohrady Department of Pathology pays non établi dans la noticeÉtablissement de santé
-
Biopticka Laborator (Czechia) pays non établi dans la noticeEntreprise
-
Masaryk Memorial Cancer Institute Department of Oncological Pathology pays non établi dans la noticeStructure de recherche
-
Masaryk University pays non établi dans la noticeUniversité ou école supérieure
-
St. Anne's University Hospital Brno pays non établi dans la noticeÉtablissement de santé
-
University Hospital Hradec Králové pays non établi dans la noticeÉtablissement de santé
-
University of Ostrava pays non établi dans la noticeUniversité ou école supérieure
-
University Hospital Ostrava Department of Clinical and Molecular Pathology and Medical Genetics pays non établi dans la noticeÉtablissement de santé
-
First Faculty of Medicine Department of Pathology pays non établi dans la noticeUniversité ou école supérieure
Department of Pathology — Charles University, Department of Pathology and Molecular Medicine — Thomayer University Hospital et General University Hospital in Prague, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.